Trial Profile

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nemtabrutinib (Primary) ; Zilovertamab vedotin (Primary)
Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Richter's syndrome
Focus Adverse reactions; Therapeutic Use
Acronyms waveLINE-006
Sponsors Merck Sharp & Dohme

22 May 2026 Planned number of patients changed from 275 to 189.
12 Mar 2026 Status changed from recruiting to active, no longer recruiting.
18 Nov 2025 Planned primary completion date changed from 13 Mar 2029 to 17 May 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com